Check-Cap Ltd. (NASDAQ:CHEK – Get Free Report) saw a significant decline in short interest in October. As of October 31st, there was short interest totalling 14,200 shares, a decline of 13.4% from the October 15th total of 16,400 shares. Based on an average daily volume of 14,900 shares, the days-to-cover ratio is currently 1.0 days. Currently, 0.3% of the shares of the stock are sold short.
Wall Street Analyst Weigh In
Separately, StockNews.com started coverage on Check-Cap in a research note on Sunday. They issued a “sell” rating on the stock.
Read Our Latest Stock Analysis on CHEK
Check-Cap Trading Up 3.3 %
Check-Cap Company Profile
Check-Cap Ltd., a clinical stage medical diagnostics company, engages in the development of a capsule-based screening technology that utilizes ultra-low-dose X-rays to scan the inner lining of the colon for precancerous polyps, and other structural abnormalities in Israel. Its C-Scan system consists of C-Scan Cap, an X-ray scanning capsule for detection of suspected polyps; C-Scan Track, a disposable system attached to the patient's back through biocompatible adhesive skin patches; and C-Scan View software, a client/server-based application that enables procedure data download from the C-Scan Track, data analysis, and report generation.
Further Reading
- Five stocks we like better than Check-Cap
- What Do S&P 500 Stocks Tell Investors About the Market?
- Is Monolithic Power Systems a Screaming Buy After Near 40% Drop?
- What is Insider Trading? What You Can Learn from Insider Trading
- Applied Materials Market Capitulates: Now is the Time to Buy
- Basic Materials Stocks Investing
- 3 Ultra-High Dividend Yield Stocks for the New Year
Receive News & Ratings for Check-Cap Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Check-Cap and related companies with MarketBeat.com's FREE daily email newsletter.